One hundred fifty-eight patients have been treated in the Triveneto region with radium 223 since its introduction. The median overall survival and progression-free survival was 14.2 and 6.2 months, respectively. Eastern Cooperative Oncology Group performance status, increased alkaline phosphatase, and alkaline phosphatase changes were prognostic for survival. Comparable outcome with a pivotal study and similar reports were confirmed. The high progression rate at first assessment (62%) shows that only some patients obtained a clear benefit. Background: Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting. Patients and Methods: We conducted a multicenter retrospective analysis in the Triveneto region of Italy. Results: One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P ¼ .0062; 0 vs. 2, P ¼ .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ! 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P ¼ .05). Patients with a baseline alkaline phosphatase (ALP) value ! 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P ¼ .029) and PFS (P ¼ .002). There was no difference according to the line of therapy (0 vs. ! 1; P ¼ .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia. Conclusion: This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined.
Introduction
Prostate cancer (PCa) is the most prevalent malignancy in Western countries, and the second leading cause of cancer-related mortality in men.
1,2 Nine of 10 patients are diagnosed with localized disease and managed by primary curative treatment (either surgery or radiotherapy) or active surveillance. In European countries, during the past decade, the 5-year relative survival rate for PCa steadily increased to 84%. 3 This result is undoubtedly owing to the extensive use of prostate-specific antigen (PSA) screening, despite the opposite side of the coin being over-diagnosis and over-treatments. 4 However, the risk of developing metastatic disease during long-term follow-up is not negligible and can range cumulatively from 26% to 38% after radical prostatectomy or other curative approaches. Moreover, around 4% of the patients are initially diagnosed with metastatic disease, 5 and morbidity and mortality by PCa are mainly caused by metastases. Therefore, there is an unmet need to improve our ability to stratify patients according their risk of disease progression and to predict the treatment outcome. The aim of treatment for metastatic prostate cancer (mPCa) is to halt, or at least to slow down, the disease progression: medical castration, using a luteinizing-releasing hormone agonist or antagonist, or bilateral orchiectomy is the most common first-line therapy (androgen deprivation therapy [ADT]). 6 Furthermore, recently presented data have shown a significant benefit in overall survival (OS) from adding 6 courses of docetaxel to ADT at diagnosis in patients with metastatic prostate cancer and high-volume disease at presentation. 7 Based also on the subsequent results of the STAM-PEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) and GETUG (Genitourinary Group) AFU15 (Association Française d'Urologie) trials, 8, 9 the addition of docetaxel to ADT should now be considered the standard of care for men with metastatic hormone-sensitive prostate cancer who are newly diagnosed with metastatic disease. 8 More recently, data from the 2017 American Sociaty of Clinical Oncology Annual Meeting indicated a survival gain from the addition of abiraterone acetate to ADT in mPCa at first presentation. 10, 11 When the disease progresses and metastasizes despite castrated levels of testosterone, it becomes metastatic castration-resistant prostate cancer (mCRPC). 12 In this setting, treatment strategies have traditionally consisted of hormonal therapy (abiraterone or enzalutamide), [13] [14] [15] [16] In November 2013, radium 223 gained approval from the Italian National Drugs Authority and has been introduced in clinics for patients with mCRPC.
Because different drugs can be used in first-or second-line therapy and some of them can be used in both settings, the best treatment sequence is still debated, and no definitive data are available. The treatment choice is best accomplished within a prostate unit, where different specialists discuss the patient's history and disease and make a personalized decision, taking into account the extent of bone disease, the severity of symptoms related to the disease, response to previous treatments, comorbidities, and, finally, the patients' preference. The multidisciplinary discussion is of paramount importance because in Italy, both medical oncologists and radiation oncologists may prescribe the drug, but it is the nuclear medicine physician who ultimately perform the injections and is responsible for the radioprotection of patients and staff.
More in detail, the collocation of therapy with radium 223 among the several treatment options for patients with mCRPC is not currently defined because the registration trial was conducted against placebo and no comparative trials are available. In this complex scenario, there is a strong rationale to collect multicenter real-world data about patients treated with radium 223 in clinical practice in order to evaluate the patterns of use of this agent and to analyze tolerability and long-term outcomes in a less selected range of patients with mCRPC compared with the registrative trial. Such analysis may help to define the characteristics of patients who will most easily benefit from treatment and then guide future therapeutic choices and the design of novel clinical trials.
We therefore planned a retrospective multicenter analysis on the characteristics and outcomes of patients treated in 13 centers in Italy during the first 3 years of availability of the drug, aiming to collect data on the tolerability and efficacy of radium 223.
Materials and Methods

Population
We designed a multicenter retrospective analysis on patients with mCRPC treated with radium 223 in the Triveneto Region, outside of clinical trials. All the medical oncology units, radiation oncology units, and nuclear medicine units of the Triveneto Region were invited to support this retrospective trial. Thirteen different institutions joined the study. Key inclusion criteria were histologic confirmation of PCa; presence of symptomatic skeletal metastases and absence of visceral metastatic disease; disease progression after therapy with a luteinizing-releasing hormone agonist or antagonist, with or without anti-androgen drugs (bicalutamide, flutamide);
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Radium223 in mCRCP in the Triveneto Italian Region previous treatment with docetaxel administered for either castrationsensitive or -resistant PCa was allowed but not mandatory; exposure to at least 1 cycle of therapy with radium 223 was mandatory. All patients had to have adequate bone marrow reserve (at baseline: absolute neutrophil count ! 1.5 Â 10 9 /L, platelets ! 100 Â 10 9 /L, and hemoglobin ! 10.0 g/dL).
Radium 223 has been administered according to current label authorization in Italy: only patients who received at least 1 cycle were enrolled.
Primary Endpoint
The primary endpoint of the trial was to evaluate the OS of patients with mCRPC treated with radium 223 according to Italian label registration.
Secondary Endpoints
Co-secondary end points of this retrospective analysis were to: (1) Evaluate progression free survival (PFS) of radium 223 according to Prostate Cancer Working Group 3 (PCWG3) criteria; (2) Evaluate the response rate according to clinical and radiologic criteria; (3) Evaluate the rate of the patients who completed the 6 cycles of therapy and the number and causes of early interruptions; (4) Evaluate the clinical benefit rate; (5) Evaluate the safety of the treatment; and (6) Analyze prognostic and predictive values of clinical parameters, PSA and ALP.
Data Collection
We retrospectively collected data from patients' clinical charts: histology, date of diagnosis for prostate cancer and development of mCRPC; data on previous radiotherapy and/or surgery; presence of lymph nodal disease at baseline; sites of disease; number and characteristics of previous treatments; number of cycles of radium 223; biochemical values (ALP, PSA, hemoglobin, neutrophils, and lymphocytes) at baseline and at the end of treatment; ECOG PS; toxicities according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.3 criteria; onset of skeletal-related events (SRE); best biochemical and radiologic response; date of progression; and survival. The study has been conducted collecting data of the eligible patients and considering all the variables.
Timepoints
All the data of the trial have been evaluated at baseline before treatment with radium 223, and whenever applicable, at the end of the treatment and at progression.
Response Assessment
We evaluated the best response according to PCWG3 criteria; therefore, we integrated the standard radiologic Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with symptomatic signs of progression and variations of biomarker during the therapy.
Statistical Consideration
Clinical data were used for descriptive statistics. Progression was measured from the beginning of the treatment until radiologic or clinical progression (defined by PCWG3 criteria) or death. Patients lost to follow-up were censored for progression at last date known to be free of progression. OS was calculated from the beginning of the treatment to death for any cause. Survival of patients lost to follow-up was checked with the national demographic registry. PFS and OS were estimated using the Kaplan-Meier method, and subgroups according to different collected variables were compared with the log-rank test.
Ethical Consideration
The study was approved by the Ethics Committee at Istituto Oncologico Veneto on May 21, 2018.
Results
Population
Since its introduction in Italy in November 2013, 158 patients have received radium 223 in the Triveneto region. The median age of the whole cohort of patients was 72 years old (range, 52-82 years), and most of them were in good general condition (ECOG PS 0 ¼ 78, 49%; ECOG PS 1 ¼ 66, 42%; ECOG PS ! 2 ¼ 14, 9%). The median baseline PSA value was 335.6 ng/mL (range, 0.33-4552 ng/ mL) and the median ALP value was 256 U/L (range, 19.2-3028 U/L). The majority of the patients had received previous radical therapy for PCa (radical prostatectomy: 70 patients, 44%; radical radiation therapy: 60 patients, 38%). Forty-six (26%) patients had baseline lymph nodal disease, whereas 58 (37%) patients had a significant disease extension at baseline, defined as 20 or more bone lesions. Global population characteristics are outlined in Table 1 .
Treatment
Radium 223 has been administrated in different lines of treatment for mCRPC: 41 (26%) patients received alpha-emitter treatment in first-line, 37 (23%) in second-line, 33 (20%) in third-line, and the other 47 (30%) in fourth-or further line of treatment. Eighty-seven (55%) patients had been exposed to docetaxel before starting radium 223. About 78% (124) of the patients were receiving bisphosphonate at the time of inclusion in the treatment with radium 223.
Most of our patients received the standard number of 6 cycles of radium 223, although at least one-fourth (37 patients; 23%) interrupted the therapy early because of disease progression.
At the time of writing, 11 patients were still on treatment. 
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Response
One hundred sixteen patients were evaluable for response according to the treating physician, having undergone at least a first disease assessment during the treatment. Of these, 71 (62%) patients achieved progression; 28 (24%) patients had stable disease, and 17 (14%) patients had partial response. The overall response rate was 14%.
For 109 patients, changes of PSA level before and after treatment were available. In 18 patients, there was any kind of PSA reduction, with 7 patients having a reduction greater than 50%. The PSA variation did not correlate with survival or response.
During alpha-emitter therapy, 20 (13%) patients experimented an SRE. Moreover, 47% of patients experienced a benefit in term of pain reduction during treatment when compared with baseline.
Survival
After a median follow-up time of 9.5 months, 75 patients have died. The median OS was 14.2 months, whereas the median PFS was 6.2 months (Figure 1 ). We analyzed survival data stratifying patients according to different predefined parameters. ECOG PS was prognostic for survival (median OS, 18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1 P ¼ .0062; 0 vs. 2 P ¼ .0002) (Figure 2 ), whereas previous prostatectomy or docetaxel exposure were not. Patients with a baseline ALP value ! 220 U/L had worse OS and PFS (10.5 vs. 24.1 months and 5.5 vs. 7.2 months, respectively; P < .001) (Figure 3) . At the same time, patients with a reduction of their ALP value during the treatment achieved a better OS (17.7 vs. 12.3 months; P ¼ .029) and PFS (7.2 vs. 5.6 months; P ¼ .002).
We also analyzed the possible impact of the line of treatment on survival: we found no significant difference according to the line of therapy (OS 0 previous treatment vs. ! 1, 14.2 vs. 14.1 months; P ¼ .490). When stratifying patients for specific previous lines of therapy, there was no evidence of any impact of the line of treatment on OS (median OS, 14.2 vs. 17.1 vs. 15.2 vs. 13.2 vs. 9.2 months, for 0, 1, 2, 3, or 4 previous lines of treatment, respectively; P ¼ .371).
As an exploratory analysis, we also analyzed the neutrophil to lymphocytes ratio (NLR); data were available for 135 patients. We found that an NLR greater than 3 was associated with increased OS (18.1 vs. 9.7 months; P < .001) and slightly associated with PFS (6.6 vs. 5.6 months; P ¼ .05) (Figure 4 ). 
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No difference in OS or PFS was appreciable according to the development of SREs during the treatment (14.2 vs. 10.2 months; P ¼ .331 and 6.3 vs. 5.8 months; P ¼ .346, respectively).
Toxicities
The main grade 3/4 toxicities were anemia (13%), asthenia (6%), and thrombocytopenia (3.5%). All the adverse events collected in this retrospective analysis are reported in Table 2 .
Discussion
Radium 223 is one of the therapeutic options to be offered to patients with metastatic PCa, who become resistant to castration with ADT, with or without antiandrogens. It has been approved based on a randomized clinical trial that attained the main survival endpoints, showing a significant reduction of the risk of death compared with placebo. 19 We have reported here a large 
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In the ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) trial, 921 patients were randomized to active treatment or placebo, with a median age of 71 years and a general good PS (ECOG 0 þ 1, 87% in the active arm and 86% in the placebo arm). Our unselected cohort of patients appears to be roughly comparable with the randomized trial, as reported in Table 1 , although some differences should be noted. In the present retrospective cohort, the median baseline PSA value was slightly higher (356 vs. 146 ng/mL), and the number of patients exposed to bisphosphonate was higher in our cohort (78% vs. 41%). Although no data are available from the randomized trial, in our cohort, 74% of the patients had been pretreated with at least 1 drug for mCRPC. Furthermore, in our cohort, we reported a rate of 23% for early interruption of radium 223 owing to radiologic or clinical disease progression, whereas in the randomized trial, 37% of the patients did not complete the treatment, although in this case the reasons were not discussed.
It is known that the randomized trial was terminated early, when an interim analysis showed a greater median OS for the radium 223 arm. The median OS in the updated analysis was 14.9 months. 19 With the limitation of a retrospective analysis, in our cohort of unselected patients, the median OS was 14.2 months, which is again superimposable to the registrative trial and similar to another reported Italian cohort, in which the median OS was 17.5 months, even if it was only estimated (the median OS had not been reached at the time of reporting). 20 On the other hand, few data are available for PFS. In our population, we found a median PFS of 6.2 months, which is exactly the observed data in the other Italian cohort. We also analyzed different biochemical parameters in our population. Specifically, baseline PSA level did not impact on response or survival, similar to previous exposure to docetaxel. In fact, homogeneous results have previously been reported in other studies. 19, 20 We also focused on ALP values. We found that an ALP value greater than 220 U/L at baseline correlates with a worse outcome, confirming available published data. 21, 22 In fact, a higher ALP value accompanies a higher tumor burden, which carries a reduced chance for response. At the same time, a decrease at least of 30% in the ALP value during treatment anticipated a greater OS and PFS, again as already published in other experiences. 23 Speculatively, we focused on NLR. It is widely known that the ratio between neutrophils and lymphocytes at baseline is associated with survival and response to treatment with second-line chemotherapy 24 ; in patients with mCRPC treated with first-line docetaxel, it correlates with OS. 25 However, little is known about the role of NLR in the treatment with radium 223. Using the same cut-off of 3, as was previously published, we found a strong association between NLR and OS and a slight association with PFS. This finding confirms the prognostic role of NLR in mCRPC, although it comes from a retrospective analyses. We know that NLR is a valid prognostic biomarker associated with survival, PSA, and RECIST responses in patients treated with chemotherapy; changes in NLR counts during treatment may also indicate benefit. 24 NLR could become a biomarker for patients who are candidates for radium 223, useful for stratifying patients into risk classes and helping physicians in the decision-making process. In our retrospective cohort, 38% of the patients experimented a clinical benefit, defined as a response or a stabilization of the disease as the best response from radium 223. Furthermore, 14% of the patients had a partial response according to PCWG3 criteria. There was no uniformity in the evaluation methods used among different centers; however, the patients had undergone a choline positron emission tomography scan or a total body computed tomography scan along with a bone scintigraphy. It is quite uncommon to discuss response for radium 223, both because it is difficult to evaluate bone lesions with conventional imaging and because radium 223 is not used with the primary intent to induce radiologic response, which was not even evaluated in the pivotal trial. Almost one-half of our patients experienced pain relief from radium 223; in fact, 47% had some benefit in our group, compared with the 25% reported in the pivotal trial, 19 where it was one of the endpoints of the study. Finally, the safety profile of radium 223 did not differ significantly from the already reported data, 19, 20, 23 and the drug is generally quite well-tolerated. Alpha particles do not traverse the bone marrow, and therefore hematologic toxicity is limited and mainly related to the baseline hematologic status of the patients. Owing to its excretion route, non-hematologic side effects are mainly gastrointestinal, as shown in the ALSYMPCA trial. Notably, we have no comparison between radium 223 and other new therapeutic agents available for mCRPC. Although indirect comparison suffers from several biases and results across studies were not significant, we know that abiraterone and enzalutamide are easier to administer, and the variation of PSA over time helps physician to understand which patients benefit most. In addition, 61% of patients treated with radium 223 progressed at first evaluation, mainly in extra bone sites. It is thus necessary to have more predictive factors to better identify patients who can benefit from radium 223.
Therefore, the main issue still remains relating to the role of radium 223 among the therapeutic armamentarium of physicians involved in management of mCRPC. In this sense, the European Medicines Agency has recently released a communication (available at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_ document/Xofigo_20/Recommendation_provided_by_Pharmacovi gilance_Risk_Assessment_Committee/WC500252055.pdf) based on early data from the ERA 223 (A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC)) trial. The European Medicines Agency's safety committee, the Pharmacovigilance Risk Assessment Committee, has recommended restricting the use of radium 223 to patients who have had 2 previous treatments for mCRPC or who cannot receive other treatments. Therefore, patients with mCRPC should ideally be all discussed by a multidisciplinary team, where the purpose of using radium 223 to prolong OS should be emphasized along with the opportunity to administer many of the other available life-prolonging therapies. Finally, radium 223 has been administrated as a single agent for all our patients, according to Italian registration. Many patients progressed in extra-bone sites, and the possibility of integrating radium 223, which is active in the skeletal lesions, with other systemic drugs is very intriguing. However, associations must be studied with caution. In fact, we have learned from the ERA 223 study that Radium223 in combination with abiraterone acetate led to a greater incidence of bone fractures and deaths.
Conclusion
Radium 223 is a current established therapeutic option in mCRPC. This large, retrospective, real-world report on radium 223 in patients with mCRPC confirms comparable OS and PFS data with the pivotal study and similar retrospective studies, as well as the predictive role of baseline ALP value and ALP decrease during the treatment. On the other hand, the high rate of progression at first re-assessment of disease shows that only a subset of patients derives a clear benefit from this drug, and outlines the importance of close clinical, radiologic, and biochemical (ALP) monitoring of the patients during treatment with radium 223. We also outlined the role of NLR in the subset of patients with mCRPC with symptomatic bone metastases and no visceral/bulky nodal involvement, for whom no previous data are available. Until now, there is no clear evidence to support the best way to sequence all the available agents, and there is an urgent need for prospective studies to define it.
Clinical Practice Points
In this retrospective multicenter study, we analysed the clinical outcome of a large cohort of patients with mCRPC treated with radium 223 in the real-world setting, according to Italian registration label. Since its introduction in Italy in November 2013, 158 patients have received radium 223 in the Triveneto region. Eighty-seven patients had been exposed to docetaxel before starting radium 223. One hundred sixteen patients were evaluable for response: 71 (62%) patients achieved progression, 28 (24%) patients had stable disease, and 17 (14%) patients had partial response. The median OS was 14.2 months, whereas the median PFS was 6.2 months. ECOG PS was prognostic for OS (P ¼ .0002), whereas previous prostatectomy or docetaxel exposure were not. Patients with a baseline ALP value ! 220 U/ L had worse OS and PFS (P < .001). At the same time, patients with a reduction of the ALP value during the treatment achieved a better OS (P ¼ .029) and PFS (P ¼ .002). This report confirms comparable OS and PFS data of the pivotal study and similar retrospective studies, as well as the predictive role of baseline ALP value and ALP decrease during treatment. Conversely, the high rate of progression at first reassessment of disease shows that only some patients derive a clear benefit from this drug and outlines the importance of close monitoring of the patients during radium 223 treatment. Until now, no clear evidence supports the best way to sequence all the available agents, and there is an urgent need for prospective studies to define it.
